New hope for advanced breast cancer patients in major global trial
NCT ID NCT07492641
Summary
This study is testing whether a new drug called BGB-43395, when combined with letrozole, works better than current standard treatments for advanced or metastatic HR+/HER2- breast cancer. The trial will involve over 1,000 patients who haven't received prior treatment for their advanced disease. Researchers will compare the new combination against three established drugs (abemaciclib, palbociclib, or ribociclib) plus letrozole to see which approach better controls cancer growth and extends survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR+ HER2- BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.